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Objectives This study was conducted to test the hypothesis that cardiac micro-ribonucleic acid (miR) profiling in severe
heart failure patients at the time of ventricular assist device (VAD) placement would differentiate those who re-
mained VAD-dependent from those with subsequent left ventricular (LV) recovery.
Background The relationship of myocardial miR expression to ventricular recovery is unknown.
Methods We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consisting of test and validation co-
horts from 2 institutions: 14 with subsequent LV recovery and VAD removal and 14 clinically matched VAD-dependent
patients. Apical core myocardium was studied for expression of 376 miRs by polymerase chain reaction (PCR) array
and real-time-PCR methods. Samples from 7 nonfailing hearts were used in confirmatory studies.
Results By PCR array, 10 miRs were differentially expressed between LV recovery and VAD-dependent patients in the
test cohort. The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, 1.5-fold;
23a, 2.2-fold; 26a, 1.4-fold; and 195, 1.8-fold; all p  0.04 vs. VAD dependent). The validation cohort simi-
larly showed lower miRs expression in LV recovery patients (23a, 1.8-fold; and 195, 1.5-fold; both p  0.03).
Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p 
0.04 vs. VAD dependent). The LV recovery patients also had significantly smaller cardiomyocytes by quantitative
histology in both cohorts.
Conclusions Lower cardiac expression of miRs 23a and 195 and smaller cardiomyocyte size at the time of VAD placement
were associated with subsequent LV functional recovery. Differential expression of miRs at VAD placement may
provide markers to assess recovery potential. (J Am Coll Cardiol 2011;58:2270–8) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.041Despite the beneficial effects of mechanical unloading
achieved after ventricular assist device (VAD) placement
on molecular markers and cardiomyocyte structure and
function in the failing heart (1–7), only a small number of
VAD-supported patients recover sufficient function to
allow permanent removal of the VAD (8 –10). Current
data suggest that an unappreciated percentage of VAD-
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November 22, 2011:2270–8 MicroRNA Signature of Ventricular Recovery(9 –12) but there are few studies that identify biochemical
markers associated with functional recovery sufficient to
allow device removal (13,14).
Micro-ribonucleic acids (miRs) are short (21 to 23 nucle-
otides long) noncoding ribonucleic acids (RNAs) that may
play potent and widespread roles in post-transcriptional
regulation of gene expression. These miRs affect diverse
pathways including apoptosis, cell growth and proliferation,
oncogene suppression and activation, and stem cell activa-
tion (15). Recent human and animal studies have shown
significant alterations in cardiac miR expression patterns
with heart failure, while others demonstrated miR involve-
ment in key heart failure pathways (16–24).
In this study, we investigated patterns of cardiac miR
expression at the time of VAD placement to identify patterns
associated with functional recovery from severe heart failure in
VAD-supported patients. We also investigated whether this
“recovery potential” expression profile was induced in failing
hearts by introduction of VAD support. Finally, we assessed
this miR profile in nonfailing control hearts.
Methods
Patient selection and tissue collection. All studies were
performed under protocols approved by the University of
Pittsburgh, Texas Heart Institute, and Cleveland Clinic
Foundation institutional review boards.
Test cohort. The test cohort consisted of 14 heart failure
patients with LV tissue samples (cores) obtained and
banked at the time of VAD placement. The recovered group
(n  7) consisted of patients who recovered sufficient
ardiac function to allow VAD removal. Recovered patients
ere compared with VAD-implanted patients who re-
ained VAD dependent (dependent group, n  7), and
who were retrospectively matched for clinical variables
associated with recovery so as to closely approximate those
variables in the recovered group patients. Patients with isch-
emic heart disease were excluded from all groups reported in
this study. Of the 7 explanted and discharged patients, 1 had
unexplained death1.5 months after discharge and 1 died3
onths post-explantation due to Staphylococcus aureus medias-
initis with preserved cardiac function. The remaining 5 have
urvived free of heart failure 6 months.
alidation cohort. The validation cohort tissue provided by
he Texas Heart Institute arose from 7 recovered patients and
dependent patients (as defined for the test cohort, and
atched for clinical variables). All 7 explanted patients sur-
ived and were free of heart failure symptoms for 6 months.
atient selection pre- and post-VAD. Paired LV sam-
les, collected at the time of VAD implantation (pre-VAD)
nd cardiac transplantation (post-VAD), were obtained
rom an independent third group of 6 patients (University of
ittsburgh) with severe heart failure from nonischemic
ardiomyopathy.
onfailing hearts. Nonfailing human heart tissue (non-ailing) was obtained from the Cleveland Clinic Founda- (ion. Transmural samples of the
ateral LV wall were obtained
rom unmatched donors whose
earts were not suitable for
ransplantation despite normal
entricular structure and function
s measured by echocardiogra-
hy. Nonfailing samples were
linically matched with the test
nd validation cohorts for age
nd sex (n  7, age 36  10
ears, 50% female).
CR and histological analysis. A screening miR polymer-
se chain reaction (PCR)-based array was performed on the
est cohort, followed by confirmatory individual quantitative
CR in the test and validation cohorts (25). The miRs
onfirmed as altered in both cohorts were tested in nonfail-
ng hearts. Measurement of cardiomyocyte size was per-
ormed in both cohorts (6,26). Details of procedures and
ata analysis are provided in the Supplemental Methods
ection (Online Appendix).
tatistical analyses. The miR expression data are pre-
ented as fold up or down regulation in the dependent group
ersus recovered (26). A negative value indicates lower expres-
ion in the recovered group. For confirmatory PCR, data are
xpressed as fold up or down expression in dependent versus
ecovered, or between pre-VAD and post-VAD samples, or
ormalized to the mean of nonfailing samples for nonfailing
ersus recovered or dependent. Results were compared be-
ween groups by a nonparametric 1-way analysis of variance
Kruskal-Wallis test). Upon detection of overall significance,
imited hypothesis driven post-hoc analyses were performed
sing Mann-Whitney U test. For pre-VAD versus post-VAD,
paired t test was employed. All data are reported as mean 
D. Significance was accepted at p  0.05.
esults
atient characteristics. Within each cohort (Table 1),
arameters at the time of VAD implantation were not signif-
cantly different between recovered and dependent groups.
owever, there were significant differences between the co-
orts: the validation cohort had more male patients, greater LV
iameters, a longer duration of heart failure before VAD
mplantation, longer time on VAD support, and more patients
n rotary VAD support. Table 1 also lists clinical parameters
hile on VAD support, and follow-up LV ejection fraction 6
onths after VAD explantation in the recovered groups of
oth cohorts. Test and validation cohorts differed in the
uration of support and EF at 6 months post-explantation.
creening real-time PCR array. In the test cohort, 6 of 7
atients in each group were first analyzed by real-time PCR
rray for miR expression. Of 376 miRs studied in the test
ohort, 141 were expressed at a level of 35 cycle threshold
Abbreviations
and Acronyms
LV  left ventricular
miR  micro-ribonucleic
acid
PCR  polymerase chain
reaction
RNA  ribonucleic acid
VAD  ventricular assist
deviceCt) in at least 1 VAD core sample; 108 were detected in
tion; LV
P
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were differentially expressed between the recovered and
dependent groups (p  0.05) (Fig. 1, Table 2). The miRs
previously reported to play roles in heart failure relevant
pathways were not differentially expressed (miRs 1, 21,
133a, 133b, and 208) (15–24).
Real-time PCR confirmation. TEST COHORT. The ex-
pression of 9 differentially expressed miRs was examined
using Taqman PCR in 6 patients in both groups of the test
cohort. Of the 9 miRs studied, miRs 15b, 23a, 26a, and 195
were confirmed as significantly altered between recovered
and dependent groups (p  0.05) (Table 2, Fig. 2). The
10th miR (181b) could not be confirmed in the test cohort
because of limitation of RNA availability but was tested in
the validation cohort. In the seventh patient from each
group of the test cohort, Taqman PCR was used to measure
the expression of 8 miRs (1, 15b, 21, 23a, 26a, 133a, 133b,
195), and the reference small RNA RNU48.
VALIDATION COHORT. The 4 miRs confirmed to be differ-
entially expressed in the test cohort, along with miR 181b,
were similarly measured in the validation cohort. The miRs
Characteristics of Patients Demonstrating Clinical Similarity Betweand Dep ndent Groups Before VAD implantat on in Both Test and VTable 1 Characteristics of Patients Demo strating Clinical Simand Dependent Groups Before VAD implantation in Bot
Test Cohort
Recovered Dependent p Value Recover
Clinical Ch
n 7 7 7
Age, yrs 40 12 42 15 NS 27 8
Percent ischemic 0 0 NS 0
Inotropic support 100% 100% NS 85%
Intra-aortic balloon pump 43% 57% NS 43%
Other mechanical support
(TandemHeart)
0% 0% NS 14%
Male 50% 50% NS 71%
EF before VAD, % 18 5 15 5 NS 18 5
LVEDD before VAD, cm 6.0 0.8 6.2 0.8 NS 7.0 1.0
PCWP before VAD, mm Hg* 26 9 27 10 NS 27 5
Cardiac index before VAD,
l/min/m2*
1.9 0.89 2.0 0.73 NS 1.6 0.2
Duration of CHF, days 62 49 75 58 NS 680 11
Type of VAD, % rotary 14% 14% NS 71%
Days on VAD 53 31 61 29 NS 433 25
Clinical Characteristics at
n 5 5 7
Beta-blocker use while
on VAD
67% 83% NS 100%
ACE inhibitor use while
on VAD
83% 83% NS 85%
EF at 6 months
post-explantation, %
55 5 N/A — 43 1
Values are n, mean  SD, or n (%). Duration of congestive heart failure was defined as the time i
on VAD was defined as time to VAD explant (recovered group) or transplantation (dependent group
*Pulmonary capillary wedge pressure and cardiac index measured immediately before VAD impla
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; EF  ejection frac
CWP  pulmonary capillary wedge pressure.23a and 195 had significant differential expression (Table 2,Fig. 3). Expression of miRs 15b, 26a, and 181b was not
significantly different, although the direction of change was the
same as in the test cohort. Combining the 2 datasets demon-
strated that miR 15b was also differentially expressed (p 0.03).
COMPARISON WITH NONFAILING HEART TISSUE. The 2
miRs, 23a and 195, found differentially expressed in both
test and validation cohorts were measured in nonfailing LV
tissue. Expression of both miR 23a and 195 was signifi-
cantly increased in the dependent groups compared with
nonfailing or recovered samples, but was similar between
nonfailing and recovered group in both cohorts (Fig. 4).
Cardiomyocyte size determination. Fluorescent micros-
copy of wheat germ agglutinin stained cardiomyocytes from
the test cohort demonstrated that the recovered group had
a significantly smaller cardiomyocyte cross-sectional areas
when compared with the dependent group (Fig. 5A).
Independent examination by light microscopy of hematox-
ylin and eosin stained samples show that the recovered
group had significantly smaller cardiomyocyte diameters
when compared with the dependent group (Fig. 5B).
Effects of VAD support on selected miRs. To determine
ecoveredtion Cohortsy Betw en Recovered
t and Validation Cohorts
ation Cohort
Nonfailing Controls
p Value
Dependent p Value
Test vs.
Validation
Cohorts
All VAD vs.
Nonfailing
Controls
ristics at Baseline
7 7
33 9 NS 36 10 NS NS
0 NS 0 NS NS
100% NS 0 NS 0.001
14% NS 0 NS 0.001
14% NS 0 NS 0.001
71% NS 50% 0.04 NS
17 5 NS 65 10 NS 0.001
7.0 1.0 NS Data not available 0.02 Data not available
27 11 NS Data not available NS Data not available
1.8 0.41 NS Data not available NS Data not available
771 802 NS NA 0.001 NA
42% NS NA 0.01 NA
369 167 NS NA 0.001 NA
th Follow-Up Post-VAD Explantation
7 NA
85% NS NA NS
85% NS NA NS
N/A NA 0.04
rom original presentation with heart failure until ventricular assist device (VAD) placement. Days
tients on pulsatile VAD support were on Thoratec (Pleasanton, California) extracorporeal devices.
, while the patient was receiving inotropes.
EDD  left ventricular end-diastolic dimension; NA  not applicable; NS  not significant;en Ralidailarit
h Tes
Valid
ed
aracte
4
17
0
6-Mon
1
n days f
). All pa
ntationwhether miRs that were differentially expressed between
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to mechanical unloading, the expression of select miRs was
measured in a separate set of 6 paired cardiac samples
obtained at the time of VAD implantation and subsequent
cardiac transplantation. Patient characteristics are listed in
Table 3.
The VAD support did not alter expression of any of the
miRs found to be differentially expressed between the
recovered and dependent groups (Table 4). To assess
whether mechanical unloading alters expression of other
miRs, additional miRs previously shown to play a role in
heart failure (15–24) were analyzed by real-time PCR.
Whereas miRs 208 and 21 showed altered expression in
response to mechanical support (Table 4), miRs 1, 133a, and
Figure 1 miRs Differentially Expressed Between Recovered and D
Threshold detection values after normalization to small ribonucleic acid (RNA) U6
bars) (n  6 per group). In the box and whisker plot, the range of values is repres
by the bar. *p  0.05. Ct  cycle threshold; microRNA or miR  micro-ribonucleic
miRs Differentially Expressed (p < 0.05) on Screening Microarrayand Confirma ion of Expre sion by Individual Taqman Real-Time PCTable 2 m Rs Diffe ntially Expresse (p < 0.05) on Screeningand Confirmation of Expression by Individual Taqman R
miR E
Screening Microarray (Test Cohort) Confirmatory
miR ID
Fold Change
R/D p Value miR ID
Fo
miR-181b 11.38 0.002 miR-181b*
miR-424 4.38 0.027 miR-424 No
miR-376a 5.41 0.028 miR-376a No
miR-195 2.91 0.029 miR-195
miR-27a 4.18 0.032 miR-27a No
miR-23a 4.52 0.032 miR-23a
miR-103 3.69 0.044 miR-103 No
miR-26a 14.92 0.044 miR-26a
miR-142-3p 6.35 0.048 miR-142-3p No
miR-15b 12.73 0.048 miR-15b
Fold change refers to recovered (R)/dependent (D) ratio. A negative number indicates lower expre
differentially expressed by screening array, miRs 15b, 23a, 26a, and 195 showed decreased e
differentially expressed in the validation cohort. In the test cohort n  6 each recovered and depe
*MiR 181b could not be validated by this method in the test cohort, but was not significantly altered in t
Abbreviations as in Table 1.133b did not. None of these miRs, however, was differentially
altered between recovered and dependent groups.
Discussion
We report, for 2 separate patient cohorts, a pattern of
myocardial miR expression at the time of VAD placement
that is associated with subsequent LV functional recovery.
The main findings in this study are as follows. 1) In patients
with advanced nonischemic heart failure requiring VAD
support, cardiac expression of miR 23a and 195 before VAD
implantation differs between hearts with eventual recovery
of ventricular function and hearts with persistent VAD
dependence. 2) This differential expression is associated
with remission of heart failure independent of clinical
dent Patients as Detected by RT-PCR Array in Test Cohort
U44 expression in recovered group (shaded bars) and dependent group (open
by the whiskers, the upper and lower quartile by the box, and the median value
RT-PCR  real-time polymerase chain reaction.
th Pre-Amplificationoarray
ime PCR With Pre-Amplification
sion
Test Cohort) Confirmatory PCR (Validation Cohort)
ange
p Value miR ID
Fold Change
R/D p Value
N/A miR-181b* No difference NS
ence NS miR-424 N/A N/A
ence NS miR-376a N/A N/A
0.01 miR-195 1.5 0.03
ence NS miR-27a N/A NS
0.03 miR-23a 1.8 0.01
ence NS miR-103 N/A N/A
0.04 miR-26a No difference NS
ence NS miR-142-3p N/A N/A
0.04 miR-15b 1.8 0.09
n the recovered group compared with dependent. Of the 10 micro-ribonucleic acids (miRs) found
n by confirmatory polymerase chain reaction (PCR). Of these 4, miRs 23a and 195 were also
for the screening array, and n  7 each recovered and dependent for the confirmatory PCR.epen
and RN
ented
acid;R WiMicr
eal-T
xpres
PCR (
ld Ch
R/D
N/A
differ
differ
1.8
differ
2.2
differ
1.4
differ
1.5
ssion i
xpressio
ndenthe validation cohort.
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ventricle size, duration of heart failure, and duration of
VAD support. 3) Remission of heart failure is associated
Figure 2 Recovered Patients in Test Cohort Have Decreased E
Individual micro-ribonucleic acids (miRs) found differentially expressed in the scree
MiRs 15b, 23a, 26a, and 195 were confirmed to be differentially expressed. *p 
Figure 3 Recovered Patients in Validation Cohort Have Decrea
Micro-ribonucleic acids (miRs) confirmed to be differentially expressed in the test
MiRs 23a and 195, but not 15b and 26a, were differentially expressed. *p  0.0with a smaller cardiomyocyte size at the time of VAD
placement. The experimental protocol and main findings
are summarized in Figure 6.
sion of Selected miRs
rray were tested using individual polymerase chain reaction (n  7 per group).
.
xpression of miRs 23a and 195
were tested in the validation cohort (n  7 per group).xpres
ning a
0.04sed E
cohort
3.
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November 22, 2011:2270–8 MicroRNA Signature of Ventricular RecoveryAs myocardial transcriptomic biomarkers can associate
with outcomes in heart failure (27), we hypothesized that
biomarkers (such as miR expression patterns) exist at the
time of VAD implantation that are associated with the
potential for recovery. We analyzed cardiac miR expression
in patients selected to match clinical variables between the
recovered and dependent groups within each cohort (test
Figure 4 Expression of miRs 23a and 195 Is Similar in Nonfaili
With Recovered But Significantly Increased in Depend
(A and B) Data from the test cohort. (C and D) Data from the validation cohort. *
†p  0.03 dependent versus nonfailing control hearts. miR  micro-ribonucleic ac
Figure 5 Recovered Patients Have Smaller Cardiomyocytes at
(A) Representative images (20) of wheat germ agglutinin stained (green [nuclei
dependent samples, with calculated cross-sectional area in M2 (n  3 per group
of cardiomyocyte diameter (M) in the validation cohort recovered and dependentand validation). However, the 2 cohorts differed signifi-
cantly in clinical features typically associated with the
development of VAD independence. These differences
between the test and validation cohorts make the observa-
tion of a conserved relationship between miR expression
and the development of VAD independence particularly
noteworthy.
arts Compared
ersus Nonfailing
.04 dependent versus recovered;
ime of VAD Implantation
ventricular assist device (VAD) core samples from the test cohort recovered and
0.01). (B) Representative images (hematoxylin and eosin) and measurements
es (n  7 per group, *p  0.01).ng He
ent V
p  0
id.the T
blue])
, *p 
sampl
f
a
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MicroRNA Signature of Ventricular Recovery November 22, 2011:2270–8Several reports have identified specific miRs that modu-
late pathologic processes relevant to heart failure; hypertro-
phy (16,18,19,23), cell death (28), fibrosis (20,29), vascular
proliferation (30), and arrhythmias (17,31). Relevant to our
observations, it is notable that overexpression of miR 195
occurs in pressure-overload rodent hearts and that trans-
genic cardiac over-expression of miR 195 induces heart
failure (16); and that elevated miR 195 expression occurs in
rodent and human failing hearts (21,22,24). Similarly, miR
23a can mediate cardiomyocyte hypertrophy (32), and is
differentially expressed between failing and nonfailing hearts
(16,24). Congruent with the reported function of miRs 23a
and 195, our data demonstrate that hearts that eventually
recover function have smaller cardiomyocyte sizes (6,33).
Intriguingly, while VAD support has been shown to de-
crease cardiomyocyte size (1), our data demonstrate that
VAD support alone does not induce a miR expression
profile associated with functional recovery. Thus, a differ-
ential miR expression in failing hearts that eventually
recovered VAD independence suggests that underlying
pathophysiologic processes exist at the time of VAD place-
ment that differ between hearts that recover function and
hearts that do not. We did not detect differences between
the recovered and dependent hearts in the expression of
other miRs that are differentially expressed between failing
and nonfailing hearts (i.e., miRs 1, 21, 29, 125b, 130, and
133 [21,24]). The fact that they did not differ with the
ability to recover function suggests that cellular processes
associated with a more limited set of miRs (23a, 195, and
possibly 15b) are critical in defining the potential to recover
cardiac function after mechanical unloading.
There are several scenarios by which lower miRs 23a and
Clinical Characteristics of Patients With PairedSamples Obt in d at Time of VAD Placementand at Time of Transplant
Table 3
Clinical Characteristics of Patients With Paired
Samples Obtained at Time of VAD Placement
and at Time of Transplant
At baseline
n 6
Age, yrs 54 18
Percent ischemic 0
Inotropic support 100%
Intra-aortic balloon pump 50%
Other mechanical support (TandemHeart) 0%
Male 50%
EF before VAD, % 18 5
LVEDD before VAD, cm 6.6 1.2
PCWP before VAD, mm Hg 28 9
Cardiac index before VAD, l/min/m2 1.8 0.69
While on VAD
Beta-blocker use 83%
ACE inhibitor use 83%
Duration of CHF, days 210 108
Duration of VAD support, days 144 67
Beta-blocker use 67%
ACE inhibitor use 83%
Abbreviations as in Table 1.195 expression may be associated with functional recovery.
iPatients who recovered may have had less severe heart
failure, a different disease etiology that allows greater like-
lihood of recovery, or genetic variants that underlie de-
creased expression of particular miRs that mediate patho-
physiologic processes of heart failure, or the response to
mechanical unloading. The observation that recovered pa-
tients had miRs 23a and 195 levels that resembled that of
nonfailing hearts and a smaller cardiomyocyte size than
dependent hearts raises the important possibility that the
recovered patients had less severe heart failure. Although we
cannot exclude this possibility, we think that this is unlikely
given that the standard clinical measures of heart failure
(Table 1) were identical in recovered and dependent groups
from both cohorts. Regarding the role of disease etiology,
cardiac miR expression profiles differ according to heart
failure etiologies (24). However, we carefully matched the
recovered and dependent groups for clinical parameters and
etiology so as to prevent bias with diseases (such as myo-
carditis, peripartum cardiomyopathy) having a higher ca-
pacity for recovery (Online Table 1). Finally, as the recovery
population is only a small percentage of all VAD-supported
patients, it is plausible that these patients possess infrequent
miR gene variants whereby decreased miR expression is
associated with recovery from heart failure, or beneficial
response to mechanical unloading. Indeed, expression quan-
titative trait loci have been found for 20% of miRs
expressed in fibroblasts (34), and miR single-nucleotide
polymorphism have been associated with congenital heart
diseases susceptibility (35) and dilated cardiomyopathy in-
cidence (36).
Study limitations. A major limitation of this observational
study is that the list of differentially expressed miRs does not
provide insight into the mechanistic processes associated
VAD Support Alters miR Expression ButDoes Not Induce a “Recovery” MiR ProfileTable 4 V D Support Alter miR Expr ssion ButDoes Not Induce a “Recovery” MiR Profile
miR ID Selection Criteria
Fold Change
Pre-/Post-VAD p Value
miR-181b † — —
miR-424 † No difference NS
miR-376a † No difference NS
miR-195 † No difference NS
miR-27a † No difference NS
miR-23a † No difference NS
miR-103 † No difference NS
miR-26a † No difference NS
miR-142-3p † No difference NS
miR-15b † No difference NS
miR-1* Literature No difference NS
miR-21* Literature 1.6 0.04
miR-133a* Literature No difference NS
miR-133b* Literature No difference NS
miR-208* Literature 1.9 0.02
*Micro-ribonucleic acids (miRs) reported as playing key roles in heart failure (15–24) were tested
or differential expression in a separate group with paired samples obtained before ventricular
ssist device (VAD) implantation and at the time of transplantation. †MiRs differentially expressed
n recovered hearts by screening array were not altered after VAD placement in this group.
NS  not significant.
2277JACC Vol. 58, No. 22, 2011 Ramani et al.
November 22, 2011:2270–8 MicroRNA Signature of Ventricular Recoverywith recovery. One approach to find insight into mechanis-
tic processes would be to use target prediction algorithms
(e.g., Targetscan or Pictar) to develop a list of possible
messenger RNA targets. However, when analyzing miRs
23a and 195, we found little congruency in either the list of
potential messenger RNA targets identified by the 2 target
prediction programs, or the biologic pathways/processes
identified through multiple pathway analysis programs (data
not shown). The lack of convergent results may reflect either
the current limitations of these bioinformatic methods, or
the need to identify additional miRs that are differentially
expressed between the recovered and dependent groups.
Indeed, because of the rarity of VAD-supported patients
who recover cardiac function (8–10), the number of patients
studied is small, and likely underpowered for detection of all
differentially expressed miRs.
Conclusions
In summary, we report cardiac miR expression differences
that may identify which patients have the greatest potential
Figure 6 Summary of Experimental Protocol and Major Finding
miR  micro-ribonucleic acid; PCR  polymerase chain reaction; VAD  ventriculafor recovery after VAD support. Such patients may have lesssevere disease, unrecognized disease etiologies that allow for
recovery, or genetic variants that relate miR expression to
functional recovery. This “recovery” expression profile is not
induced by mechanical unloading, suggesting that the pa-
tients’ potential for recovery is already established at the
time of VAD placement. If confirmed in a larger cohort,
such information could help guide clinical decisions regard-
ing utilization of mechanical support devices.
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